When taken together, trends for apoptosis, Jak/Stat and PI3K pathway activities (Figures 3, 4, and 5) and clinical outcomes (Table S1) suggest that there are limited number of pathway profiles associated with CR patients, whereas in NR patients many different pathway mechanisms may have evolved for the leukemia to be refractory to chemotherapy. The gene discussed is PIK3CD; the disease is leukemia.